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Non-small-cell lung cancer (NSCLC) represents one of the main
causes of cancer death in Western countries and more than three
quarters of lung cancer patients become candidates for systemic
chemotherapy at some time during the course of their illness.
Cisplatin remains the cornerstone of chemotherapy and cisplatin-
based regimens have become the gold standard for the manage-
ment of this disease (Stewart and Pignan, 1995). In addition, data
from literature would also suggest the superiority of platinum-
based triplets over doublets in selected patients with advanced
NSCLC (Crinò et al, 1995; Comella et al, 2000). However,
cisplatin represents the drug with the highest negative impact in
terms of patient compliance and workload for care givers; after
four to six cycles of chemotherapy, the cumulative neurotoxicity
of cisplatin-containing regimens, often becomes severe and irre-
versible (Sculier et al, 1994). This could be considered less impor-
tant in patients with metastatic disease having short-term poor
prognosis but, for patients with earlier stage of disease and higher
probability of long-term survival, cumulative neurotoxicity is
particularly relevant as it can strongly affect the quality of life. In
addition, the administration of high-dose cisplatin, is often associ-
ated with acute and late gastrointestinal toxicities (severe
nausea/vomiting and diarrhoea) and requires hospitalization for
hyperhydration and forced diuresis. 
Over the last 10 years a large number of new active agents have
emerged, including taxanes, gemcitabine, navelbine, which have
been incorporated into cisplatin-based regimens. However, despite
encouraging response rates, no significant survival advantage
could be consistently) demonstrated; furthermore, acute and
cumulative toxicities of these new platinum-based doublets and
triplets were superimposable, or even worse, than those observed
with second generation regimens (Giaccone et al, 1998; Bonomi
et al, 2000; Crinò et al, 1999). Nevertheless, the availability of
new active agents along with the need for better tolerated combi-
nation regimens fostered further investigation in the area of non-
platinum chemotherapy regimen. 
On these grounds, we performed the present phase II study
aimed at defining the antitumour activity and toxicity profile of a
non-platinum-based triplet consisting of Gemcitabine, Ifosfamide
and Navelbine in advanced NSCLC patients. 
Gemcitabine is a nucleoside analogue with a novel mechanism
of action that showed reproducible response rate of approximately
20% in patients with untreated NSCLC. At standard doses, the
weekly administration of Gemcitabine is associated with a low
incidence of side-effects, in particular myelosuppression, nausea,
vomiting and alopecia (Sheperd, 1995). Ifosfamide is a well
known alkylating agent that binds to DNA causing strand breaks:
it showed antitumour activity against NSCLC with response rates
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ranging from 20 to 32% when administered as single agent in
previously untreated patients (Eberhardt and Niederle, 1992).
Navelbine is a semisynthetic vinca alkaloid that demonstrated less
neurologic toxicity than the parental compounds mainly due to its
selectivity for mitotic cells over axonal microtubes. Its antitumor
activity and efficacy have been very well demonstrated in phase II
and III clinical trials as single agent or in combination with plat-
inum compounds (Crawford, 1996). The significant antitumor
activity along with the favourable toxicity profile of these agents
prompted their combined use in a platinum-free regimen 
PATIENTS AND METHODS 
Eligibility 
Chemotherapy-naive patients with histologically or cytologically
proven NSCLC and an Eastern Cooperative Oncology Group
(ECOG) performance status (PS) < 2 were included. Eligible
patients were required to have bidimensionally measurable stage
IIIB disease (pleural effusion and/or supraclavicular nodes) or
metastatic disease. Adequate pre-treatment haematologic (WBC
count ≤ 4000/µ l, hemoglobin ≥ 10 g/dl), hepatic (bilirubin < twice
above normal level) and renal (creatinine < twice above normal
limit) functions were also mandatory. Patients with symptomatic
brain metastases were excluded. Staging procedures consisted of:
bronchoscopy, chest X-ray, CT scan, abdominal ultrasound
performed within 4 weeks before the beginning of the treatment;
other types of organ-specific scanning were optional but recom-
mended in cases of symptoms or biochemical abnormalities. Re-
staging was planned every two courses of chemotherapy: all target
lesions were reassessed with the same method used at study entry
according to WHO criteria (Miller et al, 1981). All responses were
extramurally reviewed by an expert radiologist who was not aware
of the type of treatment; objective remissions had to be confirmed
4 weeks apart. Patients were evaluated weekly for toxicity
according to WHO recommendations during the whole therapeutic
program. 
Written informed consent was obtained from all patients
according to local institution policies: the study was approved by
the local IRB/ethical committee of participating institutions and
was conducted according to GCP. The study was sponsored and
monitored by Eli-Lilly Italy, while registration, data entry,
management and analysis were carried out independently at the
National Cancer Institute for Cancer Research in Genoa. 
The original chemotherapy protocol consisted of: navelbine
25 mg/sqm (as slow intravenous bolus) day 1 and day 4, gemc-
itabine 1000 mg/sqm days 1 and 4 and ifosfamide 3 g/sqm
(infused over 2 h) day 1. Mesna (sodium 2-mercaptoethane
sulfonate) was administered as uroprotection at the following
doses: 20% of the total ifosfamide dose intravenously, immedi-
ately before the drug infusion, and 40% of the total dose orally
after 4 and 8 h. Since three cases of neutropenic fever were
recorded among the first 8 cases enrolled, the protocol was
amended by reducing the dose of navelbine and gemcitabine on
day 4 to 20 mg/sqm and 800 mg/sqm respectively. Courses were
repeated every 3 weeks on an outpatient basis. All patients
received intravenous anti-HT3 antagonists and dexamethasone as
anti-emetic prophylaxis. White blood cell counts (WBC) were
performed weekly and biochemistry was determined on day 1 of
each cycle; chemotherapy on day 4 was administered with no WBC
determination. In the case of grade 4 neutropenia, ciprofloxacin
500 mg orally twice a day and fluconazole 100 mg daily were
administered until ANC > 1000/µ l. The prophylactic use of colony
stimulating factors (CSFs) was not allowed while their therapeutic
use was suggested for febrile neutropenia. In case of grade 3/4
thrombocytopenia or febrile neutropenia a 25% reduction in the
doses of the three drugs administered on day 1 was performed in
subsequent courses of chemotherapy. 
Simon’s optimal two-stage design for phase II clinical trials was
used to calculate the sample size (Simon, 1989): P0 (clinically
uninteresting true response rate) and P1 (sufficiently promising
true response rate) were set at 20% and 40% respectively. In the
first stage 19 patients had to be included: if ≤ 4 responses were
observed, accrual was stopped, otherwise 35 more patients had to
be registered. Drug combination was considered of interest if > 18
responses were observed out of 54 evaluable patients. Survival
was measured from the date of registration to death. Patients still
alive at the time of the final analysis were censored at the date in
which they were last observed. Progression-free survival was
calculated from the date of registration to the date of clinical
and/or radiological evidence of progression or death, whichever
occur first. Patients not progressed at the time of the final analysis
were censored at the date of their last tumour assessment. Survival
and time to progression were estimated using the Kaplan-Meier
method (Kaplan and Meier, 1985). 
RESULTS 
From March 1999 to March 2000, 50 chemotherapy-naive patients
from three participating institutions were registered. Accrual into
this study was stopped as soon as the number of responses required
by the statistical design was achieved. Two patients were excluded
from the analysis (one was inelegible because of age > 70 and the
other was never treated). Characteristics of the remaining 48 evalu-
ated patients were as follows: median age 63 years (range 44–69);
ECOG performance status 0 = 64.6%, 1 = 35.4%; the majority of
patients had stage IV disease (79%) and non-squamous histology
(70.8%). Patient characteristics are listed in Table 1. 
Toxicity 
Toxicity data are reported in Table 2 as the worst toxicity grade
experienced per course at any time in the trial. A total of 200
courses of chemotherapy were administered median per patient 4
(range 1–6). Myelosuppression was the most frequent side-effect:
grade 4 neutropenia was observed in 21.6% of the courses, while
grade 4 thrombocytopenia affected 2.5% of chemotherapy courses
Table 1 Patient characteristics 
Characteristic n (%) 
Total 48 
Median age years (range) 63 (44–69) 
ECOG PS 
0 31 64.6 
1 17 35.4 
Stage 
IIIB 10 20.8 
IV 38 79.2 
Histology 
Squamous 14 29.2 
Non-squamous 34 70.8 1454 E Baldini et al
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only. Twelve episodes of febrile neutropenia were observed,
including three cases among the first 8 patients treated at the
highest protocol dose; three patients were admitted for parenteral
antibiotic treatment and one of these discontinued the treatment
after the 4th course of chemotherapy. Three additional patients
interrupted the therapeutic programme early: two because of wors-
ening performance status after the 4th and 5th course respectively
and one patient because of severe skin rush requiring corticos-
teroid treatment after the second course. However, compliance to
the treatment was good in the majority of patients and the average
delivered over planned chemotherapy dose was 98%. No toxic
deaths were observed. 
Response and survival 
In the first step, 10 out of 19 patients obtained a major objective
remission; according to the statistical design we proceeded to the
second step where 25 objective responses (24 partial responses and
1 complete response) were obtained from the first 48 evaluated
patients with a response rate of 52% (95% C.I.: 37.4–66.5%).
Accrual was stopped at this point as we had already overcome the
figures we needed. Fourteen patients had stable disease (29%)
while 6 progressed during chemotherapy. Three patients were not
evaluable for response as they had received less than two courses
of chemotherapy: however, according to the ‘intention to treat’
policy, they were included in the response analysis as failures. All
objective remissions were extramurally reviewed and confirmed at
least 4 weeks apart. The median time from treatment onset and
response documentation was 6 weeks (range 6–12). The median
time to progression was 7.1 months (95% CI: 5.5–9.9) and median
overall survival was 11 months (95% CI: 9.6-NA) (Figure 1). One-
year survival was 46.5%. 
DISCUSSION 
The current availability of new active drugs for the treatment of
NSCLC provided an impulse for the investigation of cisplatin-free
regimens with high antitumour activity and good tolerability. In
the present multi-centre phase II study, three drugs with single-
agent activity against NSCLC and favourable toxicity profile,
gemcitabine, ifosfamide and navelbine, were combined, for the
first time, in a phase II study in patients with advanced disease.
The choice of the drug-combination tested in this study was based
on encouraging results obtained in a previous experience of our
group with the triplet Vinorelbine, Ifosfamide, Cisplatin (VIP) in
metastatic and locally advanced inoperable disease (Baldini et al,
1996; Baldini et al, 2000). The replacement of Cisplatin with
Gemcitabine, was carried out to reduce cisplatin-related acute and
long-term cumulative side-effects and to avoid hyperhydration and
enforced diuresis, while maintaining high antitumour activity. 
The schedule used in this phase II study, with navelbine and
gemcitabine on days 1 and 4, was chosen in order to maintain the
dose-intensity of each drug: in fact, the weekly schedule of navel-
bine, because of the overlap between drug dosing and WBC nadir,
often requires dose reductions (Gralla et al, 1998). The schedule
day 1 to day 4 allowed the delivery of full doses of the two drugs,
with no further reduction due to haematologic toxicity: the average
actual dose of chemotherapy was 98% of the planned dose, with
good treatment compliance for the majority of patients. 
As expected, acute haematologic toxicity was the predominant
side-effect of this regimen. However, grade 3–4 neutropenia was
generally short-lasting and febrile neutropenia, occurring in 6% of
the courses, was successfully managed on an outpatient basis in
most cases. None of the patients experienced peripheral neuro-
pathy or renal failure, while 9 out of 48 (18%) patients experienced
cumulative toxicity in the form of grade 3 fatigue. 
The excellent antitumour activity of this novel triplet emerges
from the early interruption of accrual once the number of responses
required by the statistical design of the study was overcome. To our
knowledge, this is the first phase II trial with the GIN regimen in
NSCLC. Our results compare favourably in terms of activity and
tolerability with those of novel cisplatin-based doublets (Crinò et al,
1997; Pirker et al, 1995) and triplets (Baldini et al, 1996; Comella
et al, 1999). In addition, our figures appear superior to those of
doublets including the same agents as in our regimen (Gridelli et al,
2000; Morere et al, 1997). Activity of the GIN regimen also
compares favourably with that of other non platinum-based triplets
(Gralla et al, 1998). The activity of the GIN regimen is particularly
interesting considering that, in our series, the majority of patients had
metastatic non squamous lung tumours suggesting that cisplatin may
not be an essential component in the chemotherapy of these histolog-
ical subtypes. In vitro experiences demonstrated that drugs such as
topotecan and cisplatin are particularly active in squamous cell carci-
noma cell lines while other drugs, including taxanes and gemc-
itabine, appear to have a higher antitumour activity in non-squamous
tumors (Loprevite et al, 1999). These in vitro data are in keeping with
some clinical observations suggesting a relationship between histo-
logic subtype and the probability of response to platinum-free or
-based regimens (Georgoulias et al, 2000; Boni et al, 1997). The
possibility of considering different chemotherapy regimens (plat-
inum vs non-platinum based) for different histological subtype in the
treatment of non-small cell lung cancer should be further explored. 
In conclusion, a non-cisplatin based chemotherapy regimen based
on a combination of gemcitabine, ifosfamide and navelbine, has
Table 2 Worst toxicity per course (WHO) 
G3% G4% 
Leucopenia 20.5 6.6 
Neutropenia 25.2 21.6 
Thrombocytopenia 4.1 2.5 
Anaemia 3.5 / 
Vomiting 2.5 / 
Skin rash 1.3 / 
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high activity and acceptable toxicity in the treatment of advanced
NSCLC and deserves further investigation within prospective
randomized studies assessing the role triplets, with or without plat-
inum, in the treatment of advanced non-small-cell lung cancer. 
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